Phase 1/2 Study of CAN103 in Subjects With Gaucher Disease

Inclusion Criteria: * Subjects have a confirmed clinical, enzymatic, and genetic diagnosis of Gaucher disease (Type 1 or Type 3); * Phase 1: Subjects with GD1 aged ≥18 years; Phase 2: Subjects with GD1 or GD3 aged ≥12 years; * Subjects have not received enzyme replacement therapy (ERT) or substrate replacement therapy (SRT) within 3 months before screening; * Subjects have GD-related anemia and one or more of the following disease manifestations: 1. Spleen volume ≥2 MN as measured by MRI, or 2. Liver volume ≥1.5 MN as measured by MRI, or 3. Platelet count ≥20 × 10\^9/L and \<100×10\^9/L. Exclusion Criteria: * Subjects have received or stopped treatment with other investigational drugs or devices within 30 days before screening or less than 5 half-lives, whichever is longer (drugs only); * Subjects have anemia due to other causes during screening, including nutritional anemia. Subjects whose nutritional anemia recovers with the treatment of iron, folic acid, or Vitamin B12 may be rescreened; * Subjects have received hepatectomy or splenectomy; * Subjects have had an allergic reaction to imiglucerase or other ERTs and their components; * Subjects have received treatment with erythropoietin, whole blood or packed red blood cell transfusions, or chronic systemic corticosteroids within 3 months before screening, or have received a platelet transfusion within 1 month before screening.